What one share of Passage Bio holds
We are a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions.
Passage Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$11.31 |
|---|---|
| Cash and investments | $7.51 |
| Book value | $1.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$21.04 | $0.01 | −$15.59 | — | $19.38 |
| 2025 | — | −$14.35 | — | — | — | $5.89 |
Common questions about Passage Bio
How much does one share of Passage Bio earn?
Over the last 12 months, Passage Bio lost $11.31 for each share.
Does Passage Bio pay a dividend?
Passage Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Passage Bio’s book value per share?
Passage Bio’s book value is $1.38 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Passage Bio have?
Each share of Passage Bio has $7.51 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.